
    accrual factor
  
['adult hodgkin lymphoma', 'adult myelodysplastic syndrome', 'blast phase chronic myelogenous leukemia, bcr-abl1 positive', 'childhood chronic myelogenous leukemia, bcr-abl1 positive', 'childhood hodgkin lymphoma', 'childhood myelodysplastic syndrome', 'chronic phase chronic myelogenous leukemia, bcr-abl1 positive', 'myelofibrosis', 'primary myelofibrosis', 'recurrent adult acute lymphoblastic leukemia', 'recurrent adult acute myeloid leukemia', 'recurrent adult non-hodgkin lymphoma', 'recurrent childhood acute lymphoblastic leukemia', 'recurrent childhood acute myeloid leukemia', 'recurrent childhood non-hodgkin lymphoma', 'recurrent chronic myelogenous leukemia, bcr-abl1 positive', 'refractory chronic myelogenous leukemia, bcr-abl1 positive', 'refractory non-hodgkin lymphoma']
['mycophenolate mofetil', 'sirolimus']

        Inclusion Criteria:

          -  Subjects must have one of the following disease categories:

               -  Acute myeloid leukemia (AML) beyond 2nd remission or relapsed/refractory disease

               -  Acute lymphoblastic leukemia (ALL) beyond 2nd remission or relapsed/refractory
                  disease

               -  Chronic myeloid leukemia (CML) beyond 2nd chronic phase or in blast crises

               -  Myelodysplastic syndrome (MDS)

               -  Myeloproliferative disorders including myeloid metaplasia and myelofibrosis

               -  High risk non-Hodgkin's lymphoma (NHL) in first remission

               -  Relapsed or refractory NHL

               -  Hodgkin's lymphoma (HL) beyond first remission

          -  Performance status by Karnofsky of >= 70% or Lansky > 70% for patients < 16 years of
             age

          -  Human leukocyte antigen (HLA) mismatched related or unrelated donor identified 8/10 or
             9/10

          -  Willingness to take oral medications during the transplantation period

          -  Willingness and ability to sign a written informed consent (assent if applicable)

        Exclusion Criteria:

          -  Prior myeloablative allogeneic or autologous HSCT

          -  Human immunodeficiency virus (HIV) infection

          -  Pregnant or lactating females

          -  Evidence of uncontrolled active infection

          -  Down syndrome

          -  Serum creatinine (CR) < 1.5mg/dl or 24 hour CR clearance < 50 ml/min

          -  Direct bilirubin > 2 x upper limit of normal (ULN)

          -  Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 2 x ULN

          -  Carbon monoxide diffusing capability test (DLCO) > 60% predicted and in children- room
             air oxygen saturation > 92%

          -  Left ventricular ejection fraction < 45% and in children-shortening fraction < 26%

          -  Fasting cholesterol > 300 mg/dl or triglycerides > 300 while on lipid lowering agents

          -  Patients who have received an investigational drug within 30 days of enrollment in
             study

          -  Patients with prior malignancies except basal cell carcinoma or treated carcinoma
             in-situ; cancer treated with curative intent > 5 years will be allowed; cancer
             treatment with curative intent =< 5 years will not be allowed
      